Texas sues Eli Lilly, adding a state-litigation layer to Lilly brand queries

Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly on August 12, 2025, accusing the drugmaker of bribing and illegally inducing medical providers to prescribe its most profitable medications, including the GLP-1 drugs Mounjaro and Zepbound, which are tirzepatide products used for diabetes and weight loss ^[1].

According to the press release from the Texas Attorney General's office, Lilly offered providers incentives such as "free nurses" and reimbursement support services designed to steer them toward prescribing the company's drugs ^[1]. The office says many of the resulting prescriptions were billed to Medicaid, producing what it calls millions of dollars in claims "tainted" by the alleged illegal marketing and quid pro quo arrangements ^[1]. Paxton's office argues this violates the Texas Health Care Program Fraud Prevention Act ^[1].

Paxton was quoted saying, "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," and that Lilly "fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health" ^[1]. The lawsuit follows an earlier legal action Paxton brought against Lilly and other pharmaceutical companies and pharmacy benefit managers, meaning this is not the state's first legal move against the company ^[1].

The filing itself, described as a petition, was made public through a link on the Attorney General's website, though the underlying legal document was not summarized in detail beyond the press release's framing of the allegations ^[1].

Why it matters for patients

This lawsuit does not allege that Mounjaro or Zepbound are unsafe or that the drugs themselves don't work as intended. The claims focus on how providers may have been influenced to prescribe them, not on the medications' clinical effects ^[1]. Patients currently taking tirzepatide products should know that the allegations concern marketing practices and Medicaid billing, not drug safety or efficacy, based on what the Attorney General's office has released so far ^[1].

For people relying on Medicaid coverage for Mounjaro or Zepbound, the case raises questions about how prescriptions were reviewed and covered, since the lawsuit specifically flags Medicaid claims as part of the alleged scheme ^[1]. It is not yet known from available sources whether this legal action could affect Medicaid coverage decisions, pricing, or access to these drugs for current or future patients.

The sources do not include a response from Eli Lilly to these allegations, so it is not known what the company's position is on the claims. It is also not known from the available materials what specific relief Texas is seeking, such as financial penalties or changes to business practices, beyond the general framing that the state aims to hold the company accountable ^[1].

What happens next

The lawsuit was filed August 12, 2025, and the case will proceed through the Texas legal system, though sources do not specify a court, docket timeline, or scheduled hearings ^[1]. The Attorney General's office describes this as building on a prior lawsuit against Lilly and other drug manufacturers and pharmacy benefit managers, suggesting continued legal scrutiny of the industry in Texas ^[1]. Details about Lilly's response, any motions to dismiss, or a trial date are not available in the sources reviewed here.